

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Sitagliptin / Simvastatin Formulation

Version 5.1      Revision Date: 26.09.2023      SDS Number: 24500-00023      Date of last issue: 20.03.2023  
Date of first issue: 21.10.2014

---

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1 Product identifier

Trade name : Sitagliptin / Simvastatin Formulation

#### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-stance/Mixture : Pharmaceutical

Recommended restrictions on use : Not applicable

#### 1.3 Details of the supplier of the safety data sheet

Company : MSD  
Innishannon  
County Cork - Ireland

Telephone : 353 214329300

E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

#### 1.4 Emergency telephone number

1-908-423-6000

---

### SECTION 2: Hazards identification

#### 2.1 Classification of the substance or mixture

##### Classification (REGULATION (EC) No 1272/2008)

Eye irritation, Category 2	H319: Causes serious eye irritation.
Skin sensitisation, Category 1	H317: May cause an allergic skin reaction.
Specific target organ toxicity - repeated exposure, Category 2	H373: May cause damage to organs through prolonged or repeated exposure.
Long-term (chronic) aquatic hazard, Category 3	H412: Harmful to aquatic life with long lasting effects.

#### 2.2 Label elements

##### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :



Signal word : Warning

---

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Sitagliptin / Simvastatin Formulation

Version 5.1      Revision Date: 26.09.2023      SDS Number: 24500-00023      Date of last issue: 20.03.2023  
Date of first issue: 21.10.2014

Hazard statements : H317 May cause an allergic skin reaction.  
H319 Causes serious eye irritation.  
H373 May cause damage to organs through prolonged or repeated exposure.  
H412 Harmful to aquatic life with long lasting effects.

Precautionary statements : **Prevention:**  
P260 Do not breathe dust.  
P273 Avoid release to the environment.  
P280 Wear protective gloves/ eye protection/ face protection.  
**Response:**  
P314 Get medical advice/ attention if you feel unwell.  
P333 + P313 If skin irritation or rash occurs: Get medical advice/ attention.  
P337 + P313 If eye irritation persists: Get medical advice/ attention.

### Hazardous components which must be listed on the label:

Simvastatin

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

May form explosive dust-air mixture during processing, handling or other means.

## SECTION 3: Composition/information on ingredients

### 3.2 Mixtures

#### Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Sitagliptin	654671-77-9	Eye Irrit. 2; H319	>= 10 - < 20
Simvastatin	79902-63-9	Skin Irrit. 2; H315 Skin Sens. 1; H317 STOT RE 1; H372	>= 2.5 - < 10

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Sitagliptin / Simvastatin Formulation

Version 5.1      Revision Date: 26.09.2023      SDS Number: 24500-00023      Date of last issue: 20.03.2023  
Date of first issue: 21.10.2014

		(Liver, muscle, optic nerve, Eye) Aquatic Chronic 2; H411	
Substances with a workplace exposure limit :			
Ascorbic acid	50-81-7 200-066-2		>= 1 - < 10

For explanation of abbreviations see section 16.

### SECTION 4: First aid measures

#### 4.1 Description of first aid measures

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.  
If easy to do, remove contact lens, if worn.  
Get medical attention.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention if symptoms occur.  
Rinse mouth thoroughly with water.

#### 4.2 Most important symptoms and effects, both acute and delayed

- Risks : May cause an allergic skin reaction.  
Causes serious eye irritation.  
May cause damage to organs through prolonged or repeated exposure.

#### 4.3 Indication of any immediate medical attention and special treatment needed

- Treatment : Treat symptomatically and supportively.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Sitagliptin / Simvastatin Formulation

Version 5.1      Revision Date: 26.09.2023      SDS Number: 24500-00023      Date of last issue: 20.03.2023  
Date of first issue: 21.10.2014

---

### SECTION 5: Firefighting measures

#### 5.1 Extinguishing media

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

#### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.  
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides  
Metal oxides  
Oxides of phosphorus

#### 5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

---

### SECTION 6: Accidental release measures

#### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

#### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

#### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable con-

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Sitagliptin / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
5.1	26.09.2023	24500-00023	Date of first issue: 21.10.2014

tainer for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

## SECTION 7: Handling and storage

### 7.1 Precautions for safe handling

- |                         |   |   |
|-------------------------|---|---|
| Technical measures      | : | Static electricity may accumulate and ignite suspended dust causing an explosion.<br>Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.  |
| Local/Total ventilation | : | Use only with adequate ventilation.   |
| Advice on safe handling | : | Do not get on skin or clothing.<br>Do not breathe dust.<br>Do not swallow.<br>Do not get in eyes.<br>Wash skin thoroughly after handling.<br>Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment<br>Minimize dust generation and accumulation.<br>Keep container closed when not in use.<br>Keep away from heat and sources of ignition.<br>Take precautionary measures against static discharges.<br>Do not eat, drink or smoke when using this product.<br>Take care to prevent spills, waste and minimize release to the environment. |
| Hygiene measures        | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Contaminated work clothing should not be allowed out of the workplace.<br>Wash contaminated clothing before re-use.<br>The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.  |

### 7.2 Conditions for safe storage, including any incompatibilities

- |                          |   |  |
|--------------------------|---|--|
| Requirements for storage | : | Keep in properly labelled containers. Store in accordance with |
|--------------------------|---|--|

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Sitagliptin / Simvastatin Formulation

Version 5.1      Revision Date: 26.09.2023      SDS Number: 24500-00023      Date of last issue: 20.03.2023  
Date of first issue: 21.10.2014

areas and containers      the particular national regulations.

Advice on common storage : Do not store with the following product types:  
Strong oxidizing agents  
Self-reactive substances and mixtures  
Organic peroxides  
Explosives  
Gases

### 7.3 Specific end use(s)

Specific use(s) : No data available

## SECTION 8: Exposure controls/personal protection

### 8.1 Control parameters

#### Occupational Exposure Limits

dusts non-specific      4 mg/m<sup>3</sup>  
Value type (Form of exposure): OELV - 8 hrs (TWA) (Respirable dust)  
Basis: IE OEL

10 mg/m<sup>3</sup>  
Value type (Form of exposure): OELV - 8 hrs (TWA) (inhalable dust)  
Basis: IE OEL

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Sitagliptin	654671-77-9	TWA	0.5 mg/m <sup>3</sup> (OEB 2)	Internal
Cellulose	9004-34-6	OELV - 8 hrs (TWA)	10 mg/m <sup>3</sup>	IE OEL
Starch	9005-25-8	OELV - 8 hrs (TWA) (Respirable dust)	4 mg/m <sup>3</sup>	IE OEL
		OELV - 8 hrs (TWA) (inhalable dust)	10 mg/m <sup>3</sup>	IE OEL
Simvastatin	79902-63-9	TWA	25 µg/m <sup>3</sup> (OEB 3)	Internal
	Further information: DSEN			
		Wipe limit	250 µg/100 cm <sup>2</sup>	Internal
Ascorbic acid	50-81-7	TWA	5000 µg/m <sup>3</sup> (OEB 1)	Internal

### 8.2 Exposure controls

#### Engineering measures

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Sitagliptin / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
5.1	26.09.2023	24500-00023	Date of first issue: 21.10.2014

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

### Personal protective equipment

Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection	:	
Material	:	Chemical-resistant gloves
Remarks	:	Consider double gloving.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Equipment should conform to I.S. EN 143
Filter type	:	Particulates type (P)

## SECTION 9: Physical and chemical properties

### 9.1 Information on basic physical and chemical properties

Physical state	:	powder
Colour	:	pink
Odour	:	No data available
Odour Threshold	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Sitagliptin / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
5.1	26.09.2023	24500-00023	Date of first issue: 21.10.2014

---

Lower explosion limit / Lower flammability limit : No data available

Flash point : Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

pH : No data available

Viscosity  
Viscosity, kinematic : Not applicable

Solubility(ies)  
Water solubility : No data available

Partition coefficient: n-octanol/water : Not applicable

Vapour pressure : Not applicable

Relative density : No data available

Density : No data available

Relative vapour density : Not applicable

Particle characteristics  
Particle size : No data available

### 9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : Not applicable

Molecular weight : No data available

---

## SECTION 10: Stability and reactivity

### 10.1 Reactivity

Not classified as a reactivity hazard.

### 10.2 Chemical stability

Stable under normal conditions.



# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Sitagliptin / Simvastatin Formulation

Version 5.1      Revision Date: 26.09.2023      SDS Number: 24500-00023      Date of last issue: 20.03.2023  
Date of first issue: 21.10.2014

---

### 10.3 Possibility of hazardous reactions

Hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.  
Can react with strong oxidizing agents.

### 10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.  
Avoid dust formation.

### 10.5 Incompatible materials

Materials to avoid : Oxidizing agents

### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

---

## SECTION 11: Toxicological information

### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Components:

##### Sitagliptin:

Acute oral toxicity : LD50 (Rat): > 3,000 mg/kg  
LD50 (Mouse): 3,000 mg/kg

##### Simvastatin:

Acute oral toxicity : LD50 (Rat): 5,000 mg/kg  
LD50 (Mouse): 3,800 mg/kg

##### Ascorbic acid:

Acute oral toxicity : LD50 (Rat): 11,900 mg/kg

#### Skin corrosion/irritation

Not classified based on available information.

#### Components:

##### Sitagliptin:

Species : Rabbit  
Method : Draize Test  
Result : No skin irritation

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Sitagliptin / Simvastatin Formulation

Version 5.1      Revision Date: 26.09.2023      SDS Number: 24500-00023      Date of last issue: 20.03.2023  
Date of first issue: 21.10.2014

---

### **Simvastatin:**

Species : Rabbit  
Remarks : Moderate skin irritation

### **Ascorbic acid:**

Species : Rabbit  
Method : OECD Test Guideline 404  
Result : No skin irritation

### **Serious eye damage/eye irritation**

Causes serious eye irritation.

### **Components:**

#### **Sitagliptin:**

Species : Rabbit  
Method : Draize Test  
Result : Irritating to eyes.

#### **Simvastatin:**

Species : Rabbit  
Remarks : slight irritation

#### **Ascorbic acid:**

Species : Rabbit  
Method : OECD Test Guideline 405  
Result : No eye irritation

### **Respiratory or skin sensitisation**

#### **Skin sensitisation**

May cause an allergic skin reaction.

#### **Respiratory sensitisation**

Not classified based on available information.

### **Components:**

#### **Sitagliptin:**

Test Type : Local lymph node assay (LLNA)  
Species : Mouse  
Method : OECD Test Guideline 429  
Result : Not a skin sensitizer.

#### **Simvastatin:**

Assessment : Probability or evidence of skin sensitisation in humans  
Result : positive

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Sitagliptin / Simvastatin Formulation

Version 5.1      Revision Date: 26.09.2023      SDS Number: 24500-00023      Date of last issue: 20.03.2023  
Date of first issue: 21.10.2014

---

### Ascorbic acid:

Test Type : Maurer optimisation test  
Exposure routes : Skin contact  
Species : Guinea pig  
Result : negative

### Germ cell mutagenicity

Not classified based on available information.

### Components:

#### Sitagliptin:

Genotoxicity in vitro : Test Type: Ames test  
Result: negative  
  
Test Type: Chromosome aberration test in vitro  
Test system: Chinese hamster ovary cells  
Result: negative  
  
Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)  
Test system: rat hepatocytes  
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Mouse  
Application Route: Oral  
Result: negative

#### Simvastatin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
  
Test Type: Alkaline elution assay  
Result: negative  
  
Test Type: Chromosomal aberration  
Result: negative  
  
Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Mouse  
Application Route: Oral  
Result: negative

Germ cell mutagenicity- Assessment : Weight of evidence does not support classification as a germ cell mutagen.

### Ascorbic acid:

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Sitagliptin / Simvastatin Formulation

Version 5.1      Revision Date: 26.09.2023      SDS Number: 24500-00023      Date of last issue: 20.03.2023  
Date of first issue: 21.10.2014

---

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Test Type: Chromosome aberration test in vitro  
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo  
cytogenetic assay)  
Species: Mouse  
Application Route: Ingestion  
Result: negative

### Carcinogenicity

Not classified based on available information.

### Components:

#### Sitagliptin:

Species : Mouse  
Application Route : Oral  
Exposure time : 2 Years  
Result : negative

Species : Rat  
Application Route : oral (drinking water)  
Exposure time : 2 Years  
Result : positive  
Target Organs : Liver  
Remarks : Significant toxicity observed in testing

Carcinogenicity - Assessment : Weight of evidence does not support classification as a carcinogen

#### Simvastatin:

Species : Mouse  
Application Route : Oral  
Exposure time : < 92 weeks  
Target Organs : Harderian gland  
Tumor Type : Liver, Lungs  
Remarks : The significance of these findings for humans is not certain.

Species : Rat  
Application Route : Oral  
Exposure time : 2 Years  
Tumor Type : Liver, Thyroid  
Remarks : The significance of these findings for humans is not certain.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Sitagliptin / Simvastatin Formulation

Version 5.1      Revision Date: 26.09.2023      SDS Number: 24500-00023      Date of last issue: 20.03.2023  
Date of first issue: 21.10.2014

---

### Ascorbic acid:

Species : Mouse  
Application Route : Ingestion  
Exposure time : 2 Years  
Result : negative

### Reproductive toxicity

Not classified based on available information.

### Components:

#### Sitagliptin:

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Oral  
Fertility: NOAEL Parent: 1,000 mg/kg body weight  
Result: Animal testing did not show any effects on fertility.

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Oral  
Teratogenicity: LOAEL: 250 mg/kg body weight  
Result: Embryotoxic effects and adverse effects on the offspring were detected., No teratogenic effects

Test Type: Embryo-foetal development  
Species: Rabbit  
Teratogenicity: NOAEL: 125 mg/kg body weight  
Result: No teratogenic effects

#### Simvastatin:

Effects on fertility : Test Type: Fertility  
Species: Rat, male  
Application Route: Oral  
Fertility: LOAEL: 25 mg/kg body weight

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Oral  
Embryo-foetal toxicity: NOAEL: 25 mg/kg body weight  
Result: No teratogenic effects, No adverse effects

Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Oral  
Embryo-foetal toxicity: NOAEL: 10 mg/kg body weight  
Result: No teratogenic effects, No adverse effects

Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Oral  
Embryo-foetal toxicity: LOAEL: 60 mg/kg body weight

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Sitagliptin / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
5.1	26.09.2023	24500-00023	Date of first issue: 21.10.2014

---

Result: Teratogenic potential  
Remarks: Based on data from similar materials

### Ascorbic acid:

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Ingestion  
Result: negative

### STOT - single exposure

Not classified based on available information.

### STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

### Components:

#### Simvastatin:

Target Organs : Liver, muscle, optic nerve, Eye  
Assessment : Causes damage to organs through prolonged or repeated exposure.

### Repeated dose toxicity

### Components:

#### Sitagliptin:

Species : Mouse  
NOAEL : 500 mg/kg  
LOAEL : 1,000 mg/kg  
Application Route : Oral  
Exposure time : > 2 yr  
Target Organs : Kidney

Species : Rat  
NOAEL : 500 mg/kg  
LOAEL : 1,000 mg/kg  
Application Route : Oral  
Exposure time : 14 Weeks  
Target Organs : Liver, Kidney, Heart, Teeth

Species : Dog  
NOAEL : 10 mg/kg  
LOAEL : 50 mg/kg  
Application Route : Oral  
Exposure time : 53 Weeks  
Target Organs : Central nervous system  
Symptoms : Loss of balance  
Remarks : The mechanism or mode of action may not be relevant in humans.

Species : Dog

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Sitagliptin / Simvastatin Formulation

Version 5.1      Revision Date: 26.09.2023      SDS Number: 24500-00023      Date of last issue: 20.03.2023  
Date of first issue: 21.10.2014

NOAEL : 2 mg/kg  
LOAEL : 10 mg/kg  
Application Route : Oral  
Exposure time : 27 Weeks  
Target Organs : Skeletal muscle, Central nervous system  
Symptoms : Loss of balance  
Remarks : The mechanism or mode of action may not be relevant in humans.

Species : Monkey  
NOAEL : 100 mg/kg  
Application Route : Oral  
Exposure time : 14 Weeks  
Remarks : No significant adverse effects were reported

### Simvastatin:

Species : Rat  
NOAEL : 5 mg/kg  
LOAEL : 30 mg/kg  
Application Route : Oral  
Exposure time : 14 - 104 Weeks  
Target Organs : Liver, Testis, Musculo-skeletal system, Eye

Species : Dog  
LOAEL : 10 mg/kg  
Application Route : Oral  
Exposure time : 14 - 104 Weeks  
Target Organs : Liver, Testis, Eye

Species : Rabbit  
NOAEL : 30 mg/kg  
LOAEL : 50 mg/kg  
Application Route : Oral  
Target Organs : Liver, Kidney

### Ascorbic acid:

Species : Rat, male  
NOAEL :  $\geq 8,100$  mg/kg  
Application Route : Ingestion  
Exposure time : 13 Weeks

### Aspiration toxicity

Not classified based on available information.

## 11.2 Information on other hazards

### Endocrine disrupting properties

#### Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Sitagliptin / Simvastatin Formulation

Version 5.1      Revision Date: 26.09.2023      SDS Number: 24500-00023      Date of last issue: 20.03.2023  
Date of first issue: 21.10.2014

---

REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

### Experience with human exposure

#### Components:

##### **Sitagliptin:**

Inhalation : Symptoms: upper respiratory tract infection, pharyngitis, Headache  
Ingestion : Symptoms: upper respiratory tract infection, nasopharyngitis, Headache, Nausea, Abdominal pain, Diarrhoea

##### **Simvastatin:**

Skin contact : Remarks: May produce an allergic reaction.  
Ingestion : Target Organs: Liver  
Symptoms: upper respiratory tract infection, Headache, Abdominal pain, constipation, Nausea  
Target Organs: Musculo-skeletal system

---

## SECTION 12: Ecological information

### 12.1 Toxicity

#### Components:

##### **Sitagliptin:**

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 60 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 39 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 2.2 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 201

Toxicity to microorganisms : EC50 : > 150 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

NOEC : 150 mg/l  
Exposure time: 3 h

---



# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Sitagliptin / Simvastatin Formulation

Version 5.1      Revision Date: 26.09.2023      SDS Number: 24500-00023      Date of last issue: 20.03.2023  
Date of first issue: 21.10.2014

---

Test Type: Respiration inhibition

Toxicity to fish (Chronic toxicity) : NOEC: 9.2 mg/l  
Exposure time: 33 d  
Species: Pimephales promelas (fathead minnow)  
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 9.8 mg/l  
Exposure time: 21 d  
Species: Daphnia magna (Water flea)  
Method: OECD Test Guideline 211

### Simvastatin:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 2.91 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 3.5 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 25 mg/l  
Exposure time: 96 h

NOEC (Pseudokirchneriella subcapitata (green algae)): 25 mg/l  
Exposure time: 96 h

Toxicity to microorganisms : EC50 : > 30 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

NOEC : 21 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

### Ascorbic acid:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 1,020 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203

Toxicity to microorganisms : EC50 : 140 mg/l  
Exposure time: 16 h  
Method: DIN 38 412 Part 8

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Sitagliptin / Simvastatin Formulation

Version 5.1      Revision Date: 26.09.2023      SDS Number: 24500-00023      Date of last issue: 20.03.2023  
Date of first issue: 21.10.2014

---

### 12.2 Persistence and degradability

#### Components:

##### **Sitagliptin:**

Biodegradability : Result: not rapidly degradable  
Biodegradation: 39.7 %  
Exposure time: 28 d  
Method: OECD Test Guideline 314

Stability in water : pH: 7  
Hydrolysis: 50 %(401 d)  
Method: OECD Test Guideline 111

##### **Simvastatin:**

Biodegradability : Result: rapidly degradable

Stability in water : Hydrolysis: 50 %(3.2 d)

##### **Ascorbic acid:**

Biodegradability : Result: Readily biodegradable.  
Biodegradation: 97 %  
Exposure time: 5 d  
Method: OECD Test Guideline 302

### 12.3 Bioaccumulative potential

#### Components:

##### **Sitagliptin:**

Partition coefficient: n-  
octanol/water : log Pow: -0.03

##### **Simvastatin:**

Partition coefficient: n-  
octanol/water : log Pow: > 4.07

##### **Ascorbic acid:**

Partition coefficient: n-  
octanol/water : log Pow: -1.85

### 12.4 Mobility in soil

#### Components:

##### **Sitagliptin:**

Distribution among environ-  
mental compartments : log Koc: 4.37

### 12.5 Results of PBT and vPvB assessment

#### Product:

Assessment : This substance/mixture contains no components considered

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Sitagliptin / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
5.1	26.09.2023	24500-00023	Date of first issue: 21.10.2014

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

### 12.6 Endocrine disrupting properties

#### **Product:**

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

### 12.7 Other adverse effects

No data available

## SECTION 13: Disposal considerations

### 13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

## SECTION 14: Transport information

### 14.1 UN number or ID number

ADN : Not regulated as a dangerous good  
ADR : Not regulated as a dangerous good  
RID : Not regulated as a dangerous good  
IMDG : Not regulated as a dangerous good  
IATA : Not regulated as a dangerous good

### 14.2 UN proper shipping name

ADN : Not regulated as a dangerous good  
ADR : Not regulated as a dangerous good  
RID : Not regulated as a dangerous good  
IMDG : Not regulated as a dangerous good  
IATA : Not regulated as a dangerous good

### 14.3 Transport hazard class(es)

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Sitagliptin / Simvastatin Formulation

Version 5.1      Revision Date: 26.09.2023      SDS Number: 24500-00023      Date of last issue: 20.03.2023  
Date of first issue: 21.10.2014

---

**ADN** : Not regulated as a dangerous good  
**ADR** : Not regulated as a dangerous good  
**RID** : Not regulated as a dangerous good  
**IMDG** : Not regulated as a dangerous good  
**IATA** : Not regulated as a dangerous good

### 14.4 Packing group

**ADN** : Not regulated as a dangerous good  
**ADR** : Not regulated as a dangerous good  
**RID** : Not regulated as a dangerous good  
**IMDG** : Not regulated as a dangerous good  
**IATA (Cargo)** : Not regulated as a dangerous good  
**IATA (Passenger)** : Not regulated as a dangerous good

### 14.5 Environmental hazards

Not regulated as a dangerous good

### 14.6 Special precautions for user

Not applicable

### 14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

---

## SECTION 15: Regulatory information

### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII) : Conditions of restriction for the following entries should be considered:  
Number on list 75  
If you intend to use this product as tattoo ink, please contact your vendor.

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or not.

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59) : Not applicable

Regulation (EC) No 1005/2009 on substances that deplete the ozone layer : Not applicable

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Sitagliptin / Simvastatin Formulation

Version 5.1      Revision Date: 26.09.2023      SDS Number: 24500-00023      Date of last issue: 20.03.2023  
Date of first issue: 21.10.2014

---

Regulation (EU) 2019/1021 on persistent organic pollutants (recast) : Not applicable  
Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals : Not applicable  
REACH - List of substances subject to authorisation (Annex XIV) : Not applicable  
Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances. Not applicable

### Other regulations:

Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

### The components of this product are reported in the following inventories:

AICS : not determined  
DSL : not determined  
IECSC : not determined

### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

---

## SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

### Full text of H-Statements

H315 : Causes skin irritation.  
H317 : May cause an allergic skin reaction.  
H319 : Causes serious eye irritation.  
H372 : Causes damage to organs through prolonged or repeated exposure.  
H411 : Toxic to aquatic life with long lasting effects.

### Full text of other abbreviations

Aquatic Chronic : Long-term (chronic) aquatic hazard  
Eye Irrit. : Eye irritation  
Skin Irrit. : Skin irritation  
Skin Sens. : Skin sensitisation  
STOT RE : Specific target organ toxicity - repeated exposure  
IE OEL : List of Chemical Agents and Carcinogens with Occupational Exposure Limit Values - Code of Practice, Schedule 1 and 2  
IE OEL / OELV - 8 hrs (TWA) : Occupational exposure limit value (8-hour reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Sitagliptin / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
5.1	26.09.2023	24500-00023	Date of first issue: 21.10.2014

Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

### Classification of the mixture:

Eye Irrit. 2	H319
Skin Sens. 1	H317
STOT RE 2	H373
Aquatic Chronic 3	H412

### Classification procedure:

Calculation method
Calculation method
Calculation method
Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Sitagliptin / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
5.1	26.09.2023	24500-00023	Date of first issue: 21.10.2014

---

IE / EN